CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: WDR4 (ImmuneEditome ID:10785)

1. Gene summary of enriched editing regions for WDR4

check button Gene summary
Gene informationGene symbol

WDR4

Gene ID

10785

GeneSynonymsGAMOS6|MIGSB|TRM82|TRMT82|Wuho|hWH
GeneCytomap

21q22.3

GeneTypeprotein-coding
GeneDescriptiontRNA (guanine-N(7)-)-methyltransferase non-catalytic subunit WDR4|TRM82 tRNA methyltransferase 82 homolog|WD repeat-containing protein 4|protein Wuho homolog|tRNA (guanine-N(7)-)-methyltransferase subunit WDR4
GeneModificationdate20230329
UniprotIDP57081
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr21:42843381-42844007:-ENST00000330317.5ENSG00000160193.10WDR4intronicAluJr,(T)n,AluSx3,L1ME3Achr21:42843381-42844007:-.alignment
chr21:42845840-42847041:-ENST00000330317.5ENSG00000160193.10WDR4intronicAluJb,AluJr,L1ME3A,AluSx1chr21:42845840-42847041:-.alignment


Top

2. Tumor-specific enriched editing regions for WDR4


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr21:42843381-42844007:-HNSCEER9.6768e-04image
chr21:42845840-42847041:-HNSCEER1.9450e-02image
ENSG00000160193.10,WDR4HNSCEAG1.7581e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr21:42843381-42844007:-BLCAPathEER3.1991e-021.4418e-020.1305image
ENSG00000160193.10,WDR4BLCAPathEAG1.9585e-025.6767e-030.1459image
chr21:42845840-42847041:-HNSCPathEER1.3096e-021.4147e-030.1926image
chr21:42843381-42844007:-THCAPathEER2.2126e-023.0146e-030.1462image
ENSG00000160193.10,WDR4UCSCliEAG4.9006e-022.2949e-02-0.3120image
chr21:42845840-42847041:-UVMPathEER3.1082e-021.2907e-020.4104image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for WDR4


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr21:42843381-42844007:-COADEERENSG00000269906,RP11-248J18.20.19524.0246e-026.6373e-130.4421imageNCSTF2T;FUSNANeutrophilsGSVA_HALLMARK_BILE_ACID_METABOLISM
chr21:42843381-42844007:-GBMEERENSG00000181804,SLC9A90.37603.0374e-034.3342e-070.4354imageNCSTF2T;DDX54;FUSNAMonocytesGSVA_HALLMARK_MYC_TARGETS_V2
chr21:42843381-42844007:-UVMEERENSG00000134900,TPP2-0.44264.9211e-039.5829e-05-0.4324imageNCSTF2T;DDX54;FUSTPP2T_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr21:42843381-42844007:-UVMEERENSG00000134759,ELP2-0.43196.8210e-034.5539e-05-0.4499imageNCSTF2T;DDX54;FUSELP2Macrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr21:42843381-42844007:-UVMEERENSG00000111196,MAGOHB-0.42027.0914e-032.2893e-04-0.4107imageNCSTF2T;DDX54;FUSNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr21:42843381-42844007:-UVMEERENSG00000028310,BRD9-0.39301.3934e-022.7477e-04-0.4059imageNCSTF2T;DDX54;FUSNAT_cells_CD8GSVA_HALLMARK_UV_RESPONSE_DN
chr21:42843381-42844007:-UVMEERENSG00000137815,RTF1-0.38361.8218e-022.1369e-04-0.4124imageNCSTF2T;DDX54;FUSNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr21:42843381-42844007:-READEERENSG00000107341,UBE2R20.50574.5378e-022.0693e-050.4370imageNCSTF2T;DDX54;FUSNAMacrophages_M0GSVA_HALLMARK_NOTCH_SIGNALING
chr21:42843381-42844007:-TGCTEERENSG00000117226,GBP30.34137.4417e-042.1350e-100.4849imageNFUSGBP3Mast_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_UP
chr21:42843381-42844007:-TGCTEERENSG00000128016,ZFP360.29634.7391e-036.2616e-080.4205imageNCSTF2T;DDX54;FUSZFP36Mast_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_UP
chr21:42845840-42847041:-DLBCEERENSG00000243927,MRPS60.76198.5118e-031.2571e-040.6106imageNHNRNPL;PCBP2NAB_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr21:42845840-42847041:-DLBCEERENSG00000110046,ATG2A-0.64272.7917e-021.7933e-04-0.5995imageNHNRNPL;PCBP2NAB_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr21:42845840-42847041:-DLBCEERENSG00000099381,SETD1A-0.63224.0687e-022.0910e-03-0.5094imageNHNRNPL;PCBP2NAB_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr21:42845840-42847041:-DLBCEERENSG00000115904,SOS1-0.59634.6374e-021.5264e-03-0.5225imageNHNRNPL;PCBP2SOS1Macrophages_M2GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr21:42845840-42847041:-DLBCEERENSG00000211706,TRBV6-1-0.62904.7049e-021.7547e-02-0.4049imageNNTRBV6-1T_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr21:42845840-42847041:-OVEERENSG00000173575,CHD2-0.41981.5335e-071.0704e-10-0.4168imageNHNRNPL;PCBP2NAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr21:42845840-42847041:-OVEERENSG00000120948,TARDBP-0.41323.0244e-072.3736e-11-0.4298imageNHNRNPL;PCBP2NAMacrophages_M1GSVA_HALLMARK_COAGULATION
chr21:42845840-42847041:-OVEERENSG00000183617,MRPL540.41513.1984e-072.3029e-160.5149imageNHNRNPLNAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr21:42845840-42847041:-OVEERENSG00000143553,SNAPIN0.40865.7798e-072.1951e-130.4672imageNNSNAPINT_cells_CD8GSVA_HALLMARK_DNA_REPAIR
chr21:42845840-42847041:-OVEERENSG00000133030,MPRIP-0.40616.1230e-071.1222e-10-0.4163imageNHNRNPL;PCBP2NAMacrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

4. Enriched editing regions and immune related splicing for WDR4


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000160193.10,WDR4
COADEAGMEXENSG00000129657.10chr1777213917:77215740:77215896:77215909:77215922:77215935:77216023:772160360.16372.0270e-034.9833e-100.4287imageNACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28A;LIN28B;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM6;RNF219;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF2;UPF1;WTAP;YTHDC1;YTHDF1;ZC3H7BNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr21:42843381-42844007:-
COADEERMEXENSG00000129657.10chr1777213917:77215740:77215896:77215909:77215922:77215935:77216023:772160360.15824.3298e-032.5249e-090.4205imageNCSTF2T;DDX54;FUSNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
ENSG00000160193.10,WDR4
GBMEAGIRENSG00000109736.10chr42930564:2930953:2931060:2931150-0.36581.3260e-025.0360e-07-0.4194imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28A;LIN28B;MBNL1;MOV10;MSI1;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF2;UPF1;YTHDC1;YTHDF1MFSD10MonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
ENSG00000160193.10,WDR4
OVEAGIRENSG00000167792.7chr1167606943:67607055:67608395:67608457-0.36601.2153e-062.3451e-12-0.4169imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28A;LIN28B;METTL3;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF2;UPF1;YTHDC1;YTHDF1NAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr21:42845840-42847041:-
OVEERIRENSG00000149743.9chr1164223798:64224717:64224794:64224970-0.31877.3552e-053.2323e-09-0.4159imageNHNRNPL;PCBP2NAT_cells_CD8GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr21:42845840-42847041:-
OVEERIRENSG00000177426.16chr183455151:3455258:3456353:3456437-0.42468.1049e-081.5634e-11-0.4398imageNHNRNPL;PCBP2NAB_cells_naiveGSVA_HALLMARK_DNA_REPAIR
ENSG00000160193.10,WDR4
OVEAGIRENSG00000213865.3chr866676218:66676902:66677641:66677954-0.38985.6653e-083.3677e-12-0.4240imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;NONO;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;U2AF2;UPF1NANK_cells_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr21:42845840-42847041:-
OVEERIRENSG00000240344.4chr2200884901:200885367:200885697:200885772-0.36441.9159e-063.5851e-09-0.4088imageNHNRNPL;PCBP2PPIL3T_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr21:42845840-42847041:-
OVEERIRENSG00000010322.11chr352480138:52480295:52480878:52481037-0.37251.9432e-062.2781e-10-0.4216imageNHNRNPL;PCBP2NISCHNK_cells_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr21:42845840-42847041:-
OVEERIRENSG00000167792.7chr1167606943:67607055:67608395:67608457-0.34158.9792e-059.0078e-11-0.4192imageNHNRNPL;PCBP2NAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

5. Enriched editing regions and immune infiltration for WDR4


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr21:42843381-42844007:-ACCEERT_cells_follicular_helper6.6508e-03-0.3905image
ENSG00000160193.10,WDR4ACCEAGT_cells_follicular_helper1.1426e-02-0.3659image
chr21:42843381-42844007:-BLCAEERT_cells_CD4_naive1.8157e-03-0.1657image
chr21:42845840-42847041:-BLCAEERMacrophages_M17.3857e-040.2367image
ENSG00000160193.10,WDR4BLCAEAGMacrophages_M11.0299e-030.1725image
chr21:42845840-42847041:-BRCAEERNK_cells_activated2.6026e-050.1571image
ENSG00000160193.10,WDR4BRCAEAGT_cells_CD4_naive4.7911e-020.0636image
chr21:42843381-42844007:-CESCEERMast_cells_activated9.0604e-03-0.1557image
chr21:42845840-42847041:-CESCEERT_cells_regulatory_(Tregs)3.1063e-02-0.1617image
ENSG00000160193.10,WDR4CESCEAGMast_cells_activated3.7585e-03-0.1711image
chr21:42845840-42847041:-CHOLEERMast_cells_resting2.7866e-030.6062image
ENSG00000160193.10,WDR4CHOLEAGMonocytes4.0753e-050.6676image
chr21:42843381-42844007:-COADEERMast_cells_resting9.5747e-030.1669image
ENSG00000160193.10,WDR4COADEAGNK_cells_resting7.7046e-030.1678image
chr21:42845840-42847041:-DLBCEERNK_cells_activated1.0315e-020.4341image
ENSG00000160193.10,WDR4DLBCEAGNK_cells_activated2.2269e-020.3328image
chr21:42843381-42844007:-ESCAEERPlasma_cells2.4401e-03-0.2410image
ENSG00000160193.10,WDR4ESCAEAGPlasma_cells7.3055e-03-0.2113image
chr21:42845840-42847041:-GBMEERNK_cells_resting4.8898e-020.1965image
ENSG00000160193.10,WDR4GBMEAGT_cells_gamma_delta1.0806e-020.2204image
chr21:42843381-42844007:-HNSCEERMacrophages_M23.3802e-020.1050image
chr21:42845840-42847041:-HNSCEERT_cells_regulatory_(Tregs)1.3101e-020.1399image
ENSG00000160193.10,WDR4HNSCEAGMacrophages_M21.1714e-020.1201image
chr21:42843381-42844007:-KICHEERB_cells_memory2.1544e-020.3310image
ENSG00000160193.10,WDR4KICHEAGB_cells_memory5.2246e-030.3818image
chr21:42843381-42844007:-KIRPEERNeutrophils3.9782e-03-0.2033image
chr21:42845840-42847041:-KIRPEERNeutrophils1.1622e-030.3250image
ENSG00000160193.10,WDR4KIRPEAGNeutrophils4.3175e-02-0.1390image
chr21:42843381-42844007:-LAMLEERB_cells_memory5.6540e-030.2895image
chr21:42845840-42847041:-LAMLEERMonocytes4.0582e-040.3190image
ENSG00000160193.10,WDR4LAMLEAGMonocytes5.8651e-040.2987image
chr21:42843381-42844007:-LGGEERT_cells_CD89.0022e-03-0.1285image
chr21:42845840-42847041:-LGGEERT_cells_CD4_memory_activated4.4135e-030.1700image
ENSG00000160193.10,WDR4LGGEAGMacrophages_M01.6384e-02-0.1132image
chr21:42845840-42847041:-LIHCEERT_cells_regulatory_(Tregs)2.5914e-02-0.3357image
chr21:42843381-42844007:-LUSCEERT_cells_CD86.4232e-040.1704image
chr21:42845840-42847041:-LUSCEERT_cells_CD4_memory_activated4.9676e-030.1613image
ENSG00000160193.10,WDR4LUSCEAGT_cells_CD83.0070e-030.1443image
chr21:42843381-42844007:-MESOEERNeutrophils2.6505e-020.2671image
ENSG00000160193.10,WDR4MESOEAGNK_cells_resting4.3202e-02-0.2390image
chr21:42845840-42847041:-OVEERT_cells_CD81.2317e-030.2160image
ENSG00000160193.10,WDR4OVEAGT_cells_CD84.0527e-030.1763image
chr21:42845840-42847041:-PAADEERB_cells_memory1.8329e-030.3452image
ENSG00000160193.10,WDR4PAADEAGDendritic_cells_resting4.0586e-02-0.1752image
chr21:42845840-42847041:-PCPGEERT_cells_regulatory_(Tregs)1.4184e-020.3519image
chr21:42843381-42844007:-PRADEERT_cells_CD4_memory_resting3.1941e-030.1567image
chr21:42845840-42847041:-PRADEERB_cells_naive5.3913e-04-0.2481image
ENSG00000160193.10,WDR4PRADEAGT_cells_CD4_memory_resting2.6002e-030.1549image
chr21:42845840-42847041:-READEERB_cells_naive2.3767e-020.2644image
chr21:42843381-42844007:-SARCEERMonocytes1.6170e-020.1678image
ENSG00000160193.10,WDR4SARCEAGMonocytes5.6663e-030.1855image
chr21:42843381-42844007:-SKCMEERT_cells_CD82.6407e-040.1757image
chr21:42845840-42847041:-SKCMEERT_cells_CD82.1715e-040.1959image
ENSG00000160193.10,WDR4SKCMEAGT_cells_CD84.2094e-060.2176image
chr21:42843381-42844007:-STADEERMacrophages_M21.9217e-030.1805image
chr21:42845840-42847041:-STADEERB_cells_naive1.8510e-03-0.1703image
ENSG00000160193.10,WDR4STADEAGB_cells_memory1.7174e-03-0.1684image
chr21:42843381-42844007:-TGCTEERMast_cells_resting5.7529e-040.2752image
chr21:42845840-42847041:-TGCTEERDendritic_cells_activated6.0506e-030.2482image
ENSG00000160193.10,WDR4TGCTEAGMast_cells_resting2.4915e-050.3327image
chr21:42843381-42844007:-THCAEERDendritic_cells_activated5.8786e-030.1353image
chr21:42845840-42847041:-THCAEERMast_cells_activated2.4583e-020.1551image
ENSG00000160193.10,WDR4THCAEAGNK_cells_resting1.4839e-020.1165image
chr21:42845840-42847041:-UCECEERT_cells_CD82.4225e-020.2957image
ENSG00000160193.10,WDR4UCECEAGT_cells_CD81.4040e-030.2520image
chr21:42843381-42844007:-UCSEERMast_cells_resting1.1462e-020.3514image
ENSG00000160193.10,WDR4UCSEAGB_cells_naive4.9196e-02-0.2715image
chr21:42843381-42844007:-UVMEERMacrophages_M21.5865e-020.2759image
chr21:42845840-42847041:-UVMEERT_cells_regulatory_(Tregs)5.0901e-030.4569image
ENSG00000160193.10,WDR4UVMEAGMacrophages_M22.0069e-020.2663image


Top

6. Enriched editing regions and immune gene sets for WDR4


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000160193.10,WDR4ACCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.1168e-020.3148image
chr21:42843381-42844007:-ACCGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.6593e-020.3478image
chr21:42845840-42847041:-BLCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.9049e-030.2182image
ENSG00000160193.10,WDR4BLCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG6.1568e-060.2360image
chr21:42843381-42844007:-BLCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.5394e-050.2185image
chr21:42845840-42847041:-BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.3195e-080.2113image
chr21:42843381-42844007:-BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER3.7659e-040.1178image
ENSG00000160193.10,WDR4BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG3.1719e-080.1766image
chr21:42845840-42847041:-CESCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.2673e-020.1521image
ENSG00000160193.10,WDR4CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0065e-03-0.1938image
chr21:42843381-42844007:-CESCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.5189e-03-0.1886image
chr21:42845840-42847041:-CHOLGSVA_HALLMARK_HEME_METABOLISMEER1.1221e-020.5298image
ENSG00000160193.10,WDR4CHOLGSVA_HALLMARK_HEME_METABOLISMEAG3.4090e-020.3817image
chr21:42843381-42844007:-COADGSVA_HALLMARK_PEROXISOMEEER2.1021e-03-0.1976image
ENSG00000160193.10,WDR4COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.3763e-03-0.2009image
chr21:42845840-42847041:-COADGSVA_HALLMARK_COMPLEMENTEER3.2464e-020.1569image
chr21:42845840-42847041:-DLBCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.8805e-02-0.3751image
ENSG00000160193.10,WDR4DLBCGSVA_HALLMARK_SPERMATOGENESISEAG3.4114e-02-0.3097image
chr21:42843381-42844007:-DLBCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.7265e-02-0.3458image
chr21:42845840-42847041:-ESCAGSVA_HALLMARK_MYC_TARGETS_V2EER7.9870e-04-0.2641image
ENSG00000160193.10,WDR4ESCAGSVA_HALLMARK_MYC_TARGETS_V2EAG4.1329e-03-0.2256image
chr21:42843381-42844007:-ESCAGSVA_HALLMARK_HYPOXIAEER1.8865e-020.1878image
chr21:42845840-42847041:-GBMGSVA_HALLMARK_MYC_TARGETS_V2EER2.3652e-03-0.2993image
ENSG00000160193.10,WDR4GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG9.7182e-050.3315image
chr21:42843381-42844007:-GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.7693e-040.3011image
ENSG00000160193.10,WDR4HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.8959e-03-0.1246image
chr21:42845840-42847041:-HNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.8338e-020.1330image
chr21:42845840-42847041:-KICHGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.0378e-030.5527image
ENSG00000160193.10,WDR4KICHGSVA_HALLMARK_DNA_REPAIREAG1.2619e-02-0.3436image
chr21:42843381-42844007:-KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEER4.9106e-02-0.2856image
ENSG00000160193.10,WDR4KIRCGSVA_HALLMARK_COAGULATIONEAG2.2182e-030.1868image
chr21:42843381-42844007:-KIRCGSVA_HALLMARK_HYPOXIAEER9.5990e-040.2206image
chr21:42845840-42847041:-KIRPGSVA_HALLMARK_G2M_CHECKPOINTEER7.5722e-04-0.3363image
ENSG00000160193.10,WDR4KIRPGSVA_HALLMARK_NOTCH_SIGNALINGEAG3.4696e-02-0.1451image
chr21:42845840-42847041:-LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER6.3629e-030.2488image
chr21:42843381-42844007:-LAMLGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.7518e-030.3254image
ENSG00000160193.10,WDR4LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG5.7742e-030.2418image
chr21:42843381-42844007:-LGGGSVA_HALLMARK_MYC_TARGETS_V2EER7.3886e-03-0.1318image
ENSG00000160193.10,WDR4LGGGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.9045e-050.1884image
chr21:42845840-42847041:-LGGGSVA_HALLMARK_FATTY_ACID_METABOLISMEER6.0236e-070.2935image
ENSG00000160193.10,WDR4LIHCGSVA_HALLMARK_E2F_TARGETSEAG7.9771e-03-0.2117image
chr21:42843381-42844007:-LIHCGSVA_HALLMARK_E2F_TARGETSEER1.5666e-02-0.1964image
chr21:42843381-42844007:-LUADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.1289e-060.2449image
ENSG00000160193.10,WDR4LUADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG3.1920e-070.2599image
chr21:42845840-42847041:-LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER8.2043e-030.1799image
chr21:42845840-42847041:-LUSCGSVA_HALLMARK_GLYCOLYSISEER8.8092e-060.2526image
chr21:42843381-42844007:-LUSCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER7.3562e-040.1685image
ENSG00000160193.10,WDR4LUSCGSVA_HALLMARK_UV_RESPONSE_UPEAG1.2443e-050.2112image
ENSG00000160193.10,WDR4MESOGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG3.9993e-02-0.2427image
chr21:42845840-42847041:-MESOGSVA_HALLMARK_MYC_TARGETS_V2EER1.7274e-02-0.3792image
chr21:42843381-42844007:-MESOGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER3.0159e-02-0.2612image
chr21:42843381-42844007:-OVGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.2812e-060.3015image
chr21:42845840-42847041:-OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.1170e-110.4362image
ENSG00000160193.10,WDR4OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.1201e-100.3835image
ENSG00000160193.10,WDR4PAADGSVA_HALLMARK_HYPOXIAEAG1.4628e-030.2693image
chr21:42845840-42847041:-PAADGSVA_HALLMARK_P53_PATHWAYEER1.4197e-020.2749image
chr21:42843381-42844007:-PCPGGSVA_HALLMARK_E2F_TARGETSEER1.3515e-02-0.2338image
ENSG00000160193.10,WDR4PCPGGSVA_HALLMARK_MYC_TARGETS_V2EAG7.8678e-03-0.2436image
chr21:42845840-42847041:-PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7656e-020.3179image
ENSG00000160193.10,WDR4PRADGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.1765e-020.1298image
chr21:42843381-42844007:-PRADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER3.4242e-020.1129image
chr21:42845840-42847041:-PRADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.1956e-030.2063image
chr21:42845840-42847041:-READGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER4.9722e-03-0.3254image
chr21:42843381-42844007:-READGSVA_HALLMARK_HYPOXIAEER1.4022e-030.3354image
ENSG00000160193.10,WDR4READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0956e-030.3014image
chr21:42845840-42847041:-SARCGSVA_HALLMARK_COAGULATIONEER1.3326e-020.2312image
ENSG00000160193.10,WDR4SARCGSVA_HALLMARK_MYOGENESISEAG1.1447e-030.2174image
chr21:42843381-42844007:-SARCGSVA_HALLMARK_MYC_TARGETS_V2EER1.7546e-03-0.2172image
ENSG00000160193.10,WDR4SKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG5.0663e-070.2370image
chr21:42845840-42847041:-SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.7830e-040.1926image
chr21:42843381-42844007:-SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.1203e-050.1971image
chr21:42845840-42847041:-STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.7404e-070.2776image
ENSG00000160193.10,WDR4STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG5.7366e-080.2874image
chr21:42843381-42844007:-STADGSVA_HALLMARK_HEME_METABOLISMEER6.5619e-060.2599image
chr21:42845840-42847041:-TGCTGSVA_HALLMARK_G2M_CHECKPOINTEER8.2764e-06-0.3929image
chr21:42843381-42844007:-TGCTGSVA_HALLMARK_SPERMATOGENESISEER1.0970e-03-0.2614image
ENSG00000160193.10,WDR4TGCTGSVA_HALLMARK_G2M_CHECKPOINTEAG2.1761e-06-0.3710image
chr21:42845840-42847041:-THCAGSVA_HALLMARK_PEROXISOMEEER1.2063e-030.2219image
ENSG00000160193.10,WDR4THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.4849e-03-0.1357image
chr21:42843381-42844007:-THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.5913e-03-0.1430image
chr21:42843381-42844007:-THYMGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.8263e-020.1997image
chr21:42845840-42847041:-THYMGSVA_HALLMARK_DNA_REPAIREER8.4607e-030.4159image
ENSG00000160193.10,WDR4THYMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG4.7126e-020.1915image
ENSG00000160193.10,WDR4UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.4723e-040.2760image
chr21:42845840-42847041:-UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER7.9469e-030.3453image
chr21:42843381-42844007:-UCSGSVA_HALLMARK_HEME_METABOLISMEER4.7134e-030.3896image
chr21:42845840-42847041:-UCSGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.2239e-030.5176image
ENSG00000160193.10,WDR4UCSGSVA_HALLMARK_GLYCOLYSISEAG2.0696e-030.4138image
ENSG00000160193.10,WDR4UVMGSVA_HALLMARK_G2M_CHECKPOINTEAG1.0494e-02-0.2920image
chr21:42843381-42844007:-UVMGSVA_HALLMARK_PROTEIN_SECRETIONEER1.9286e-02-0.2679image


Top

7. Enriched editing regions and drugs for WDR4


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000160193.10,WDR4ACCBosutinibEAG3.9048e-020.3021image
chr21:42845840-42847041:-BLCABMS.536924EER2.8086e-06-0.3243image
ENSG00000160193.10,WDR4BLCAAxitinibEAG1.3397e-050.2275image
chr21:42843381-42844007:-BLCAAxitinibEER3.9705e-060.2430image
chr21:42845840-42847041:-BRCABryostatin.1EER7.6845e-09-0.2147image
chr21:42843381-42844007:-BRCAGDC.0449EER4.3732e-050.1352image
ENSG00000160193.10,WDR4BRCABAY.61.3606EAG1.9176e-050.1370image
chr21:42845840-42847041:-CESCCGP.60474EER1.5723e-02-0.1808image
ENSG00000160193.10,WDR4CESCErlotinibEAG1.6470e-04-0.2214image
chr21:42843381-42844007:-CESCErlotinibEER2.9066e-03-0.1773image
chr21:42845840-42847041:-CHOLA.770041EER1.0102e-020.5362image
ENSG00000160193.10,WDR4CHOLA.770041EAG9.8492e-030.4565image
chr21:42843381-42844007:-COADGW843682XEER1.0080e-030.2110image
ENSG00000160193.10,WDR4COADGW843682XEAG2.5371e-060.2920image
chr21:42845840-42847041:-COADBIRB.0796EER1.1537e-040.2790image
chr21:42845840-42847041:-DLBCBMS.536924EER4.5514e-03-0.4748image
chr21:42843381-42844007:-DLBCBosutinibEER8.3287e-03-0.3845image
ENSG00000160193.10,WDR4DLBCElesclomolEAG1.9530e-03-0.4403image
chr21:42845840-42847041:-ESCAJNJ.26854165EER9.0638e-04-0.2623image
ENSG00000160193.10,WDR4ESCACGP.60474EAG3.3659e-04-0.2800image
chr21:42843381-42844007:-ESCABexaroteneEER3.9412e-03-0.2296image
chr21:42845840-42847041:-GBMEpothilone.BEER1.5538e-030.3109image
ENSG00000160193.10,WDR4GBMBI.D1870EAG5.2680e-050.3431image
chr21:42843381-42844007:-GBMBI.D1870EER6.0427e-050.3522image
ENSG00000160193.10,WDR4HNSCBAY.61.3606EAG1.2946e-040.1815image
chr21:42843381-42844007:-HNSCBAY.61.3606EER2.1969e-020.1133image
chr21:42845840-42847041:-HNSCBMS.536924EER1.8469e-03-0.1751image
chr21:42843381-42844007:-KICHCCT018159EER3.6449e-020.3028image
chr21:42845840-42847041:-KICHJNJ.26854165EER5.3214e-03-0.4810image
ENSG00000160193.10,WDR4KICHJW.7.52.1EAG1.1190e-020.3491image
ENSG00000160193.10,WDR4KIRCA.770041EAG1.7165e-02-0.1460image
chr21:42843381-42844007:-KIRCA.770041EER3.0607e-03-0.1984image
chr21:42845840-42847041:-KIRCAP.24534EER2.1434e-020.1890image
chr21:42843381-42844007:-KIRPEtoposideEER1.5522e-030.2229image
ENSG00000160193.10,WDR4KIRPCytarabineEAG7.7127e-030.1825image
chr21:42845840-42847041:-KIRPABT.888EER1.9084e-02-0.2377image
ENSG00000160193.10,WDR4LAMLLenalidomideEAG2.0265e-030.2693image
chr21:42845840-42847041:-LAMLCI.1040EER2.9793e-03-0.2700image
chr21:42843381-42844007:-LAMLCGP.082996EER3.0632e-02-0.2280image
ENSG00000160193.10,WDR4LGGAxitinibEAG2.6096e-050.1970image
chr21:42845840-42847041:-LGGEmbelinEER7.5087e-080.3152image
chr21:42843381-42844007:-LGGGSK269962AEER3.5283e-050.2025image
chr21:42843381-42844007:-LIHCCCT018159EER1.0341e-020.2081image
ENSG00000160193.10,WDR4LIHCCCT018159EAG6.3093e-030.2178image
chr21:42843381-42844007:-LUADATRAEER4.1161e-040.1868image
chr21:42845840-42847041:-LUADABT.263EER1.7346e-030.2129image
ENSG00000160193.10,WDR4LUADATRAEAG5.0200e-040.1786image
ENSG00000160193.10,WDR4LUSCAP.24534EAG7.9277e-050.1911image
chr21:42843381-42844007:-LUSCAP.24534EER3.1633e-040.1796image
chr21:42845840-42847041:-LUSCBortezomibEER6.2198e-08-0.3052image
ENSG00000160193.10,WDR4MESOBMS.754807EAG3.6334e-03-0.3385image
chr21:42845840-42847041:-MESOBI.2536EER3.5980e-020.3369image
chr21:42843381-42844007:-MESOBMS.754807EER2.4399e-05-0.4847image
ENSG00000160193.10,WDR4OVImatinibEAG1.4113e-070.3171image
chr21:42843381-42844007:-OVCHIR.99021EER3.6925e-020.1356image
chr21:42845840-42847041:-OVMG.132EER1.8213e-09-0.3905image
ENSG00000160193.10,WDR4PAADBexaroteneEAG7.3327e-03-0.2281image
chr21:42845840-42847041:-PAADBexaroteneEER2.2712e-02-0.2561image
ENSG00000160193.10,WDR4PCPGJNK.Inhibitor.VIIIEAG1.9059e-02-0.2156image
chr21:42843381-42844007:-PCPGJNK.Inhibitor.VIIIEER2.7508e-02-0.2093image
chr21:42845840-42847041:-PCPGAZD6244EER3.1082e-02-0.3116image
chr21:42843381-42844007:-PRADGW843682XEER2.6910e-020.1180image
ENSG00000160193.10,WDR4PRADEpothilone.BEAG3.6094e-020.1081image
chr21:42845840-42847041:-PRADEmbelinEER2.5646e-030.2170image
ENSG00000160193.10,WDR4READMG.132EAG2.7814e-03-0.3134image
chr21:42843381-42844007:-READAS601245EER5.8728e-03-0.2914image
chr21:42845840-42847041:-READMG.132EER1.2375e-03-0.3709image
chr21:42843381-42844007:-SARCEmbelinEER1.2449e-030.2240image
chr21:42845840-42847041:-SARCIPA.3EER1.6065e-020.2251image
ENSG00000160193.10,WDR4SARCEmbelinEAG3.5795e-040.2380image
chr21:42843381-42844007:-SKCMMethotrexateEER3.4282e-03-0.1428image
chr21:42845840-42847041:-SKCMGNF.2EER6.3321e-06-0.2380image
ENSG00000160193.10,WDR4SKCMCGP.60474EAG9.2805e-04-0.1575image
chr21:42845840-42847041:-STADAZ628EER5.8039e-05-0.2188image
chr21:42843381-42844007:-STADJW.7.52.1EER1.6202e-04-0.2186image
ENSG00000160193.10,WDR4STADBMS.536924EAG1.1391e-06-0.2588image
ENSG00000160193.10,WDR4TGCTBI.D1870EAG1.7017e-100.4858image
chr21:42845840-42847041:-TGCTBMS.536924EER1.9947e-09-0.5117image
chr21:42843381-42844007:-TGCTBI.D1870EER7.9172e-080.4175image
chr21:42843381-42844007:-THCACytarabineEER6.0970e-040.1679image
ENSG00000160193.10,WDR4THCACytarabineEAG4.2992e-040.1677image
chr21:42845840-42847041:-THCABX.795EER7.3548e-030.1845image
chr21:42845840-42847041:-THYMAZD6482EER1.2896e-040.5750image
ENSG00000160193.10,WDR4THYMAZD7762EAG3.9962e-020.1980image
chr21:42845840-42847041:-UCECMetforminEER6.8206e-03-0.3515image
ENSG00000160193.10,WDR4UCECA.770041EAG1.6572e-06-0.3705image
chr21:42845840-42847041:-UCSDasatinibEER3.4762e-03-0.4742image
chr21:42843381-42844007:-UCSAG.014699EER4.8729e-030.3882image
ENSG00000160193.10,WDR4UCSAG.014699EAG1.4155e-030.4273image
chr21:42845840-42847041:-UVMAMG.706EER4.7293e-03-0.4603image
chr21:42843381-42844007:-UVMBicalutamideEER1.8379e-02-0.2699image
ENSG00000160193.10,WDR4UVMEmbelinEAG1.7584e-020.2717image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType